Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got a lot of news to get into today, including some big developments in oncology.
The need-to-know this morning
Sellas’ blood cancer immunotherapy cut risk of death
An experimental drug from Sellas Life Sciences reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia, the company said this morning.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Source: www.statnews.com



